Picture of Kronos Bio logo

KRON — Kronos Bio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Kronos Bio Inc reports results for the quarter ended in September - Earnings Summary

* Kronos Bio Inc  KRON.OQ  reported a quarterly adjusted
loss
of 57 cents​​ per share for the quarter ended in September. The
mean expectation of five analysts for the quarter was for a loss
of 65 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Kronos Bio Inc's reported EPS for the quarter was a loss
of 57
cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Kronos Bio Inc shares had fallen by 23.6% this quarter and
lost 81.2% so far this year.
    * The company reported a quarterly loss of $32.26 million.
    * Wall Street's median 12-month price target for Kronos Bio
Inc is
$15.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
9 at 05:24 a.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.65          -0.57          Beat
 Jun. 30 2022      -0.69          -0.59          Beat
 Mar. 31 2022      -0.66          -0.65          Beat
 Dec. 31 2021      -1.10          -1.13          Missed

Recent news on Kronos Bio

See all news